PMID- 34850772
OWN - NLM
STAT- MEDLINE
DCOM- 20220308
LR  - 20220428
IS  - 1998-4138 (Electronic)
IS  - 1998-4138 (Linking)
VI  - 17
IP  - 5
DP  - 2021 Nov
TI  - Efficacy and safety of sintilimab-based regimens against advanced gastric and 
      gastroesophageal junction adenocarcinoma.
PG  - 1234-1240
LID - 10.4103/jcrt.jcrt_856_21 [doi]
AB  - AIMS: Our study assessed the efficacy and safety of sintilimab-based regimens for 
      real-world treatment of advanced gastric and gastroesophageal junction 
      adenocarcinoma (G/GEJAC). MATERIALS AND METHODS: Cases of advanced nonresectable 
      G/GEJAC treated with sintilimab-based regimens in the Department of 
      Gastroenterology of Shanxi Provincial Cancer Hospital between December 2018 and 
      September 2020 were retrospectively examined. Endpoints included median 
      progression-free survival (mPFS), median overall survival (mOS), disease control 
      rate (DCR), objective response rate (ORR), and adverse events (AEs). Univariate 
      and multivariate analyses were conducted to determine the effect of 
      stratification factors on efficacy. RESULTS: Among the 37 included patients, mPFS 
      and mOS were 4.27 and 7.3 months, respectively. Efficacy was evaluated at least 
      once in 32 of 37 patients. The ORR and DCR were 12.5% and 65.63%, respectively. 
      Among four patients with mismatch repair deficiency/microsatellite 
      instability-high (dMMR/MSI-H) lesions, two achieved partial remission, and two 
      displayed stable disease, resulting in a DCR of 100%. The most observed AEs 
      included leukopenia, neutropenia, thrombocytopenia, nausea, and skin rash. mPFS 
      was 4.90 months in patients who received sintilimab in the first- or second-line 
      setting, versus 3.00 months in other patients. A significant survival difference 
      was found between these groups in univariate and multivariate analyses. 
      CONCLUSIONS: The application of sintilimab-based regimens achieved good disease 
      control and tolerability for the real-world treatment of advanced G/GEJAC. The 
      treatment was more effective when administered in the first- or second-line 
      setting. Patients with dMMR/MSI-H lesions may also benefit from sintilimab-based 
      regimens.
FAU - Wang, Yusheng
AU  - Wang Y
AD  - Beijing Friendship Hospital Cancer Center, Capital Medical University, Beijing; 
      Department of Gastrointestinal Oncology, Shanxi Provincial Cancer Hospital, 
      Affiliated to Shanxi Medical University, Shanxi, China.
FAU - Zhao, Jian
AU  - Zhao J
AD  - Department of Gastrointestinal Oncology, Shanxi Provincial Cancer Hospital, 
      Affiliated to Shanxi Medical University, Shanxi, China.
FAU - Yu, Hongmei
AU  - Yu H
AD  - Department of Health Statistics, School of Public Health, Shanxi Medial 
      University, Shanxi, China.
FAU - Wang, Jie
AU  - Wang J
AD  - Graduate School, Shanxi Medical University, Shanxi, China.
FAU - Zhang, Ninggang
AU  - Zhang N
AD  - Department of Gastrointestinal Oncology, Shanxi Provincial Cancer Hospital, 
      Affiliated to Shanxi Medical University, Shanxi, China.
FAU - Cao, Bangwei
AU  - Cao B
AD  - Beijing Friendship Hospital Cancer Center, Capital Medical University, Beijing, 
      China.
LA  - eng
PT  - Journal Article
PL  - India
TA  - J Cancer Res Ther
JT  - Journal of cancer research and therapeutics
JID - 101249598
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 8FU7FQ8UPK (sintilimab)
SB  - IM
MH  - Adenocarcinoma/*drug therapy/pathology
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Monoclonal, Humanized/*therapeutic use
MH  - Esophageal Neoplasms/*drug therapy/pathology
MH  - Esophagogastric Junction/*drug effects/pathology
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Retrospective Studies
MH  - Stomach Neoplasms/*drug therapy/pathology
MH  - Survival Rate
MH  - Young Adult
OTO - NOTNLM
OT  - Gastric adenocarcinoma
OT  - PD-1 inhibitor
OT  - gastroesophageal junction adenocarcinoma
OT  - sintilimab
COIS- None
EDAT- 2021/12/02 06:00
MHDA- 2022/03/09 06:00
CRDT- 2021/12/01 08:44
PHST- 2021/12/01 08:44 [entrez]
PHST- 2021/12/02 06:00 [pubmed]
PHST- 2022/03/09 06:00 [medline]
AID - JCanResTher_2021_17_5_1234_331313 [pii]
AID - 10.4103/jcrt.jcrt_856_21 [doi]
PST - ppublish
SO  - J Cancer Res Ther. 2021 Nov;17(5):1234-1240. doi: 10.4103/jcrt.jcrt_856_21.